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Commentary ʹ The CC genotype of the ERCC1 C118T single-nucleotide polymorphism 
impacts positively on the efficacy of NB-UVB therapy for vitiligo  
 
Vitiligo is a common depigmenting skin disease with a prevalence of 1-2%.
1
 Although the 
exact aetiology and detailed pathogenesis of vitiligo is not fully understood, autoreactive T 
cell responses against melanocytes are clearly involved in the development of the disease.
2,3 
Of several immunosuppressive treatments, narrow-band ultraviolet B (NB-UVB) now 
represents the phototherapy of choice for inducing repigmentation in patients with 
generalised vitiligo where depigmented areas affect multiple sites or large areas of the 
body. Indeed, more than 75% repigmentation has been achieved in over 50% of patients.
4,5
 
It is also useful for halting the progression of currently active vitiligo; stabilisation of the 
disease was evident in 80% of treated patients.
5
 Comparative studies have indicated also 
the superior efficacy and better safety profile of NB-UVB over psoralen with UVA.
6,7
 
 
As yet, the precise mechanism of action of NB-UVB in repigmenting vitiligo lesions is 
unknown. However, NB-UVB can activate the release from keratinocytes of endothelin-1 
and basic fibroblast growth factor, which stimulate melanocyte, and can stimulate the 
expression of focal adhesion kinase and matrix metalloproteinases, which may enhance 
melanocyte migration from the outer root sheath of the hair follicle into the epidermis.
8
 In 
addition, during NB-UVB irradiation, skin-infiltrating T cells are induced to apoptose due to 
the accumulation of DNA damage in the form of cyclobutane pyrimidine dimers.
9
 Repair of 
such damaged DNA is managed via the nucleotide excision repair (NER) pathway and, 
interestingly, single-nucleotide polymorphisms of the DNA repair gene APE1 have been 
associated with susceptibility to vitiligo.
10
 
2 
 
 
In this issue of the BJD, Dai et al
11 
investigated whether allelic variants of the NER gene 
ERCC1 (excision repair cross complementation 1) could influence the efficacy of NB-UVB 
treatment of vitiligo. Their study of 86 patients with active vitiligo indicated that those with 
the CC genotype of the ERCC1 C118T single-nucleotide polymorphism demonstrated higher 
levels of repigmentation as well as an earlier appearance of repigmenting lesions following 
therapy with NB-UVB. Furthermore, the T lymphocyte apoptosis rate and cyclobutane 
pyrimidine dimer levels were significantly higher in patients with the CC genotype in 
comparison to those with the TT and CT gene variants. Overall, this interesting study 
provides evidence that genetic polymorphisms of certain NER genes can positively impact 
on the outcome of NB-UVB efficacy in the treatment of vitiligo by weakening DNA repair 
mechanisms leading to T cell death and so improved repigmentation rates.    
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